RETROSPECTIVE ANALYSIS TO CHARACTERIZE THE REAL-WORLD USAGE PATTERNS OF CEFTAZIDIME-AVIBACTAM IN THE MANAGEMENT OF MDR GRAM-NEGATIVE BACTERIAL INFECTIONS IN A TERTIARY CARE CENTER

Praveen B.*, Aishwarya B. and Senthur Nambi P.

Carbapenem resistance is a rapidly spreading problem for which only a few antibiotic options exist. Ceftazidime-avibactam (CZA) is one such agent. Real-world data regarding its use is gradually accumulating. We wanted to add to this data our experience. We did a retrospective chart analysis on 100 patients who received the drug for at least 24 hours between 2021 and 2022, for suspected or proven sepsis and looked at their clinical status at days 0, 3, 7, and 21. The cultures grew for 72% of the patients, and the most common pathogen was Klebsiella pneumoniae (75%) followed by E. coli (22.2%). Carbapenem resistance was noted in 75%. All-cause-outcome of the patients who received the drug as targeted therapy (n=53) was observed as follows: Cured 42 (79.2%), not cured 11 (20.7%). Despite limitations, our study shows CZA can be an effective therapy for MDR gram-negative infections.